Ming Li (Memorial Sloan Kettering)

New T cell im­mune re­sponse dis­cov­ery points to 'out-of-box' can­cer ther­a­py op­tions

Re­searchers have iden­ti­fied a class of T cells with an un­con­ven­tion­al tu­mor-hom­ing mech­a­nism that could point the way to new types of can­cer im­munother­a­pies.

In im­mune check­point ther­a­py, mon­o­clon­al an­ti­bod­ies pre­vent PD-1, a “check­point pro­tein” on cer­tain tu­mors from bind­ing to the T cell and turn­ing the T cell off. The T cells can thus re­main on and de­stroy can­cer­ous cells pre­sent­ing with cer­tain tu­mor anti­gens.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.